We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma.
- Authors
Greenberg, Ross S.; Ruddy, Jake A.; Boyarsky, Brian J.; Werbel, William A.; Garonzik-Wang, Jacqueline M.; Segev, Dorry L.; Imus, Philip H.
- Abstract
<bold>Background: </bold>Patients with multiple myeloma (MM) were excluded from the original SARS-CoV-2 mRNA vaccine trials, which may influence vaccine hesitancy in this population. We prospectively characterized the safety and immunogenicity of two-dose SARS-CoV-2 mRNA vaccination in 44 patients with MM, who underwent vaccination from 12/17/2020 to 3/18/2021.<bold>Results: </bold>Rates adverse reactions were low and consistent with those documented in vaccine trials. Among those on MM therapy, 93% developed detectable anti-receptor binding domain (RBD) antibodies after dose 2, while 94% of patients not on MM therapy seroconverted.<bold>Conclusions: </bold>Two-dose SARS-CoV-2 mRNA vaccination is mildly reactogenic and leads to high rates of seroconversion in patients with MM. These findings can provide reassurance to MM patients who are hesitant to receive SARS-CoV-2 mRNA vaccines.
- Subjects
MULTIPLE myeloma; MESSENGER RNA; ANTIBODY formation; COVID-19 vaccines; SARS-CoV-2
- Publication
BMC Cancer, 2021, Vol 21, Issue 1, p1
- ISSN
1471-2407
- Publication type
journal article
- DOI
10.1186/s12885-021-09097-5